What's wrong with our cancer models?

Nature Reviews Drug Discovery

Volumn 4, Issue 2, 2005, Pages 161-165

  Kamb, Alexander ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CATHEPSIN K; CD20 ANTIGEN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLT3 LIGAND; FLUOROURACIL; GEFITINIB; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; IMATINIB; MIDOSTAURIN; ONCOPROTEIN; PACLITAXEL; PROTEASOME; PROTEIN BCL 2; RITUXIMAB; STEM CELL FACTOR; TELOMERASE; THYMIDINE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER MODEL; CANCER RESEARCH; CELL PROLIFERATION; CLINICAL STUDY; CYTOKINESIS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; DRUG USE; GENETIC HETEROGENEITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RELIABILITY; SIGNAL TRANSDUCTION; TREATMENT FAILURE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE III; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; TREATMENT FAILURE;

EID: 14044261316     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1635     Document Type: Article

References (18)

1. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
2. Gorre, M. E. & Sawyers, C. L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr. Opin. Hematol. 9, 303-307 (2002).
3. Kamb, A. Consequences of nonadaptive alterations in cancer. Mol. Biol. Cell. 14, 2201-2205 (2003).
4. Roberts Jr., T. G. et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292, 2130-2140 (2004).
5. Ishii, N., Robert, M., Nakayama, Y., Kanai, A. & Tomita, M. Toward large-scale modeling of the microbial cell for computer simulation. J. Biotechnol. 113, 281-294 (2004).
6. Oskoglou-Nomikos, T., Pater, J. L. & Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9 4227-4239 (2003).
7. Yingling, J. M., Blanchard, K. L. & Sawyer, J. S. Development of TGF-β signaling inhibitors for cancer therapy. Nature Rev. Drug Discov. 3, 1011-1022.
8. Peterson, J. K. & Houghton, P. J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837-844 (2004).
9. Druker, B. J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30 (2004).
10. Dancey, J. E. Predictive factors for epidermal growth factor receptor inhibitors - the bull's-eye hits the arrow. Cancer Cell 5, 411-415 (2004).
11. Tuveson, D. A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054-5058 (2001).
12. Griffin, J. D. FLT3 tyrosine kinase as a target in acute leukemias. Hematol. J. 5, S188-190 (2004).
13. Slamon, D. & Pegram, M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 28, 13-19 (2001).
14. Weisberg, E. & Griffin, J. D. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist. Updat. 6 231-238 (2003).
15. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000).
16. Jonkers, J. & Berns, A. Conditional mouse models of sporadic cancer. Nature Rev. Cancer 2, 251-265.
17. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001)
18. Wong, S. L. et al. Proc. Natl Acad. Sci. USA 101, 15682-15687 (2004).